Sensitivity to CPT-11 and platinum derivatives of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses

Masaya Mukai; Shinkichi Sato; Hiromi Ninomiya; Kanako Wakui; Nobukazu Komatsu; Naruaki Matsui; Masato Nakamura; Kyoji Ogoshi; Hiroyasu Makuuchi

doi:10.4993/acrt.15.22

Original Articles

Sensitivity to CPT-11 and platinum derivatives of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses

Masaya Mukai, Shinkichi Sato, Hiromi Ninomiya, Kanako Wakui, Nobukazu Komatsu, Naruaki Matsui, Masato Nakamura, Kyoji Ogoshi, Hiroyasu Makuuchi

Author information

Masaya Mukai
Tokai University Hachioji Hospital, Department of Surgery
Shinkichi Sato
Tokai University Oiso Hospital, Department of Pathology
Hiromi Ninomiya
Tokai University Oiso Hospital, Department of Pathology
Kanako Wakui
Tokai University Oiso Hospital, Department of Pathology
Nobukazu Komatsu
Tokai University Oiso Hospital, Department of Pathology
Naruaki Matsui
Tokai University Oiso Hospital, Department of Pathology
Masato Nakamura
Tokai University Hachioji Hospital, Department of Pathology
Kyoji Ogoshi
Tokai University School of Medicine, Department of Surgery
Hiroyasu Makuuchi
Tokai University School of Medicine, Department of Surgery

Keywords: Gastric cancer, occult neoplastic cells, CPT-11, Topoisomelase-1 inhibitor, platinum agents, Bax, ERCC-1, isolated tumor cells

JOURNAL FREE ACCESS

2007 Volume 15 Issue 1 Pages 22-26

DOI https://doi.org/10.4993/acrt.15.22

Details

Abstract

In this study, immunohistochemistry was used to detect Topo-1 and Bax/ERCC-1 expression in patients who had lymph node metastasis of stage II/III gastric cancer with occult neoplastic cells (ONCs) in their lymph node sinuses. In addition, tumor sensitivity was compared between CPT-11 and platinum agents. In the recurrence group (RG) (n=28), immunohistochemistry revealed high Topo-1 expression in 3 patients (10.7%) and low expression in 25 patients (89.3%), while there was high expression in 1 patient (11.1%) and low expression in 8 patients (88.9%) from the non-recurrence group (N-RG) (n=9) (Not significant; N.S.). Immunostaining showed high Bax/low ERCC-1 expression in 11 patients (39.3%) from the RG and other patterns of expression in 17 patients (60.7%), while high Bax/low ERCC-1 expression was observed in 3 patients (33.3%) from the N-RG and other patterns were noted in 6 patients (66.7%) (N.S.). There was a significant difference between the rate of high-Bax/low-ERCC-1 expression and high Topo-1 expression in the RG (p=0.0136). These results suggest that platinum derivatives such as CDDP are more effective than CPT-11 in both RG and N-RG of stage II/III gastric cancer with ONCs.

Corresponding author

Register with J-STAGE for free!